Leadership team - Immedica

Anders has long and solid experience from working internationally with niche and rare diseases as CEO and as a board member.

Anders Edvell

Chief Executive Officer

Anders Edvell is a Doctor of Medicines (MD), specialized in pharmaceutical medicines (University of Basel). He also holds a PhD in Cell biology and Histology, as well as an MBA from Stockholm School of Economics.

Anders is a board member of the Swedish Pharmaceutical Insurance company (LFF). Before joining Immedica he was the CEO of Unimedic Group (a regional Specialty pharma company with CDMO capabilities. Anders has a long-standing experience from working internationally with niche and rare diseases in companies such as Recip, Swedish Orphan and Sobi (where he established and developed the SPP division). He has also worked with global medical affairs at BMS.

Nina has 15 years of experience both as Senior Legal Counsel and as Vice President of Business Development.

Nina Fleck

General Counsel

Nina Fleck graduated with an LL.M. (Masters of Law) from Stockholm University in 2003.

Prior to joining Immedica, Nina worked as Senior Legal Counsel and as Vice President of Business Development at Swedish Orphan Biovitrum between 2003 and 2018

Håkan has operated in pharma management roles from R&D to commercial positions, and he has extensive experience from corporate development with an impressive deal track record.

Håkan Garpenstrand

Head of Business Development

Håkan Garpenstrand (DDS, MBA, PhD) has a long and significant track record from pharmaceutical deal-making.

Prior to Immedica, Håkan held a senior management position at Sobi, and before that he enjoyed management positions at Pfizer Sweden, Wyeth, Innoventus, and Biovitrum

Carl has over 20 years’ experience of commercializing niche specialty pharmaceuticals and orphan drug products in Europe and in the Middle East.

Carl Belmadani

Chief Commercial Officer

Carl brings extensive experience of commercializing niche specialty pharmaceuticals and orphan drug products in Europe and in the Middle East gained over 20 years.

Prior to Immedica, Carl held the position of Vice President Strategic Transactions at Sobi, and previously held several senior commercial positions including Vice President, Head of Partner Products at Sobi, Commercial Lead at Sobi, and Director of Sales at IMS health. Carl has also held several management positions in sales and marketing at Bristol-Myers Squibb. Carl has a Master of Business Administration from Stockholm Business School, Stockholm University.

Carina, RP, has more than 20 years’ experience in the Pharma Industry with focus on products manufactured on contract including supply and worldwide distribution.

Carina Carlsson

Head of Quality, Responsible Person

Carina Carlsson is the Head of Quality and Responsible Person on company wholesaler license. Carina graduated with an M.Sc. in Pharmacy from Uppsala University in 1996.

Prior to Immedica, Carina was acting as Senior Director Quality Assurance, QP/RP, at Sobi between 2011-2018. Between 2003 to 2011 Carina acted as Head of Quality at ACO Hud Nordic and Swedish Orphan. Carina has more than 20 years’ experience in the Pharma Industry with focus on products manufactured on contract including supply and worldwide distribution.

Arvid has 20 years of experience from Drug Safety in the Pharma industry he is also engaged in several Safety networks amongst others EFPIA.

Arvid Cronlund

Head of Drug Safety

Arvid Cronlund is the Head of the Drug Safety department and EU-Qualified Person for Pharmacovigilance for Immedica Pharma. He has an M.Sc in Pharmacy from Uppsala University in 1998. Arvid has 20 years of experience from Drug Safety in the Pharma industry.

Prior to Immedica he has been the Head of Drug Safety at Pfizer in Sweden and the Head of Drug Safety / EU-QPPV for Swedish Orphan Biovitrum (Sobi). Arvid has engaged in several pharmacovigilance networks including the Swedish Pharmaceutical Industry Association, EFPIA and the Swedish Pharmaceutical Society.

Simon has 20 years of CFO experience preferably from regulated and international businesses.

Simon Falk

Chief Financial Officer

Simon has a long background as CFO preferably from regulated and international businesses. Simon holds a degree in Master of science in Economics from Stockholm University.

Prior to Immedica Simon held the position as CFO for MRG Group where he was heavily involved in the listing on Nasdaq Stockholm in 2016.

Simon has also been the CFO for the pharmacy chain Kronans Apotek and for several companies in the Telenor and Tele2 Group.

Linda brings extensive experience from roles within Communications and Investor Relations in Pharma and Biotech companies.

Linda Holmström

Head of Communication

Linda is an experienced stock exchange- and corporate brand communicator. Linda is responsible for both our external corporate branding including ESG and sustainability communication as well as being tightly involved in our European launches, with focus on our digital platforms and interfaces.

Linda has extensive experience from roles within Communications and Investor Relations in Pharma and Biotech companies, mainly listed on the Stockholm Stock Exchange. Prior to joining Immedica Linda held the position as Director of Investor Relations at Oncopeptides, and before that she held senior Communications and Investor Relations positions at Sobi and Recipharm. At Recipharm she was strongly involved in the execution of the successful IPO.

Linda holds a Master of Science degree in Chemical Engineering from the Royal Institute of Technology, Stockholm as well as a Diploma in Marketing and Communications from IHM Business School.

Julia has a strong finance background with previous experience as an Auditor at Grant Thornton.

Julia Öquist

Head of Business Control

Julia holds a degree of Master of Science in Business and Economics from Lulea University of Technology.

Prior to Immedica, Julia has been working as an Auditor at Grant Thornton between 2015 and 2017.

Lena has more than 20 years of experience from various roles in the pharma industry within the area of Pricing, Market Access and Health Economics, at Country, Regional and International levels.

Lena Jacobson

Head of Market Access,
Pricing & Health Economics

Lena Jacobson holds a BSc in Business Administration and Economics and a PhLic in Health Economics from Lund University.

She joins Immedica from Allergan, where she worked as Market Access Director for Other Europe Region, headed up and led the Nordic Market Access team and, most recently, as HEOR Director in the Global HEOR team, responsible for evidence generation in the Nordics.

Prior to Allergan, she worked at Sobi, focusing on the partner product portfolio. She has also experience from working in global and regional pricing, market access and HEOR roles at BMS, Nycomed and Pfizer.

Louise has extensive experience working internationally in the commercial field, over 15 years’ experience.

Louise Mehkri

Head of Commercial Strategy
and International Business

Louise Mehkri joined Immedica in 2018. Louise graduated with an M.Sc in Economics and Business from Stockholm School of Economics in 2002.

Louise has over 15 years’ experience within the Pharma Industry. Prior to joining Immedica, Louise worked as a International Brand Portfolio Director within the field of Specialty Care at Sobi where she also built strong capabilities in Alliance Management (2014 – 2018). Prior to that, Louise has extensive experience from different commercial positions at Pfizer, Wyeth and Astra Zeneca.

With over 20 years of experience from a wide range of commercial positions, leadership and leading teams is a key principal driver for Gunilla.

Gunilla Mickelsson

Head of Europe

Gunilla Mickelsson has over 20 years of experience of leading commercial positions in the pharmaceutical industry.

Gunilla joined Immedica in 2019, coming from international positions most recently at Sedana Medical AB as VP Head of Marketing, and prior to this, Sobi. At Sobi she held several Senior Director roles, with focus on commercializing and launching orphan drugs and niche products. To add to this Gunilla has extensive experience from various roles at Pfizer, Wyeth, Meda and AstraZeneca.

Gunilla holds a degree in Master of science in Business & Economics

Heidi has more than 13 years of experience from pharmaceutical industry within medical affairs and clinical development.

Heidi Ramstad

Chief Medical Officer

Heidi Ramstad joined Immedica in April 2022 and is a Doctor of Medicines (MD) from NTNU, in Trondheim – Norway and has specialized in pediatrics.

Heidi has long-standing experience with both national, Nordic and international responsibilities as medical director and CMO at Pfizer, GSK, Roche as well as start-up biotechs.

Maj has over 20 years of experience from the Pharma industry, within research and medical affairs.

Maj Sundbom

Head of Medical Affairs

Maj Sundbom joined Immedica in 2019. She has an M.SC in Pharmacy from Uppsala University and a PhD (medical doctor) from Karolinska Institute.

Prior to Immedica Maj was senior scientist at Pharmacia/Biovitrum (1998-2011), initially with focus on metabolic diseases and later inflammation.

She has held several international positions within medical affairs at Sobi (2011-2019) and has vast experience of health care compliance from a global perspective.

Lia has a wide-ranging experience from the pharmaceutical industry within the field of regulatory affairs and quality assurance.

Lia Uppfeldt

Head of Regulatory

Lia started her career at the Swedish Medicinal Products Agency, but since 2003 she has been in the pharmaceutical industry within the field of regulatory affairs and quality assurance.

Prior to Medical, Lia was Director Regulatory Affairs at Medivir AB. Lia has also worked at Abbvie, BioPhausia and Swedish Orphan.

Lia holds a M Sc Pharm from the University of Uppsala.